Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Fiduciary Trust Co

Fiduciary Trust Co increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,522 shares of the biopharmaceutical company’s stock after acquiring an additional 26 shares during the quarter. Fiduciary Trust Co’s holdings in Regeneron Pharmaceuticals were worth $8,959,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. RPg Family Wealth Advisory LLC increased its holdings in Regeneron Pharmaceuticals by 2.8% during the 3rd quarter. RPg Family Wealth Advisory LLC now owns 5,991 shares of the biopharmaceutical company’s stock worth $6,298,000 after purchasing an additional 165 shares during the last quarter. BNP Paribas grew its position in shares of Regeneron Pharmaceuticals by 16.3% during the third quarter. BNP Paribas now owns 1,733 shares of the biopharmaceutical company’s stock worth $1,822,000 after buying an additional 243 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its stake in shares of Regeneron Pharmaceuticals by 107.1% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 20,609 shares of the biopharmaceutical company’s stock worth $21,665,000 after buying an additional 10,660 shares during the last quarter. Cravens & Co Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 5.8% in the third quarter. Cravens & Co Advisors LLC now owns 1,305 shares of the biopharmaceutical company’s stock valued at $1,372,000 after acquiring an additional 71 shares in the last quarter. Finally, Blueshift Asset Management LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at $356,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

REGN has been the subject of several research analyst reports. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price for the company. BMO Capital Markets lowered their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. JPMorgan Chase & Co. reduced their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,099.55.

Regeneron Pharmaceuticals Stock Up 0.2 %

Shares of Regeneron Pharmaceuticals stock opened at $754.87 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $735.95 and a 1-year high of $1,211.20. The company has a market capitalization of $82.95 billion, a P/E ratio of 18.68, a PEG ratio of 2.89 and a beta of 0.15. The business’s fifty day moving average price is $921.45 and its two-hundred day moving average price is $1,022.55. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.